Premium
Alpha tocopherol supplementation elevates plasma apolipoprotein A1 isoforms in normal healthy subjects
Author(s) -
Aldred Sarah,
Sozzi Tommaso,
Mudway Ian,
Grant Melissa M.,
Neubert Hendrik,
Kelly Frank J.,
Griffiths Helen R.
Publication year - 2006
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200500217
Subject(s) - proteome , apolipoprotein b , proteomics , medicine , blood proteins , placebo , endocrinology , blood plasma , biology , biochemistry , cholesterol , pathology , alternative medicine , gene
Plasma α‐tocopherol (AT) concentrations are inversely related to cardiovascular (CV) risk; however, intervention studies with AT have failed to show any consistent benefit against CV disease (CVD). Proteomics offers the opportunity to examine novel effects of AT supplementation on protein expression and therefore improve our understanding of the physiological roles of AT. Thus, to investigate the effects of AT supplementation on the plasma proteome of healthy subjects we have undertaken a double‐blind, randomised, parallel design supplementation study in which healthy subjects ( n = 32; 11 male and 21 female) consumed AT supplements (134 or 268 mg/day) or placebo capsules for up to 28 days. Plasma samples were obtained before supplementation and after 14 and 28 days of supplementation for analysis of changes in the plasma proteome using 2‐DE and MALDI‐MS. Using semiquantitative proteomics, we observed that proapolipoprotein A1 (identified by MS and Western blotting) was altered at least two‐fold. Using quantitative ELISA techniques, we confirmed a significant increase in plasma apolipoprotein A1 concentration following supplementation with AT which was both time and dose dependent ( p < 0.01 after 28 days supplementation with 268 mg AT/day). These data demonstrate the time and dose sensitivity of the plasma proteome to AT supplementation.